The ScienceDaily release from March 2026 reports that erythritol, widely used in keto snacks, diet sodas, and low-calorie products, can impair cerebral endothelial cells. It reduces their ability to relax (impairing vasodilation), raises oxidative stress, and weakens fibrinolysis, the process that breaks down blood clots. These effects were observed at concentrations matching typical human consumption. However, the coverage omits key details on study design. The underlying research appears to be a peer-reviewed laboratory investigation, likely involving in-vitro exposure of human brain microvascular endothelial cells to erythritol, but exact sample sizes, number of replicates, and statistical methods are not disclosed in the press summary. This limits assessment of reliability, a common shortcoming when translating bench science to public headlines.

This work builds directly on the 2023 peer-reviewed observational study by Witkowski et al. published in Nature Medicine, which followed more than 4,000 participants across three cohorts and found that elevated plasma erythritol levels were associated with roughly double the risk of major adverse cardiovascular events, including stroke. That study was limited by its observational design, potential dietary confounders, and inability to prove causation. The new 2026 findings supply a plausible biological mechanism focused on the brain's vasculature, an aspect largely missed in earlier coverage that centered on heart attacks.

What both the original source and much prior reporting overlooked is the broader pattern of regulatory lag with sugar alcohols and artificial sweeteners. Similar concerns emerged with aspartame in 2023 when the WHO classified it as 'possibly carcinogenic' based on limited evidence, and with sucralose studies showing gut microbiome disruption. A 2021 review in Advances in Nutrition synthesized data on multiple non-nutritive sweeteners and noted insufficient long-term human trials examining cerebrovascular outcomes. These additives received FDA GRAS status decades ago using smaller, shorter studies than current standards demand.

The combined evidence suggests millions of people managing diabetes or pursuing low-carb diets could face cumulative vascular risks that current labeling does not adequately communicate. While in-vitro results do not always translate to whole-body physiology, the consistency across the 2023 clinical data and this mechanistic study warrants caution. Larger randomized controlled human trials are urgently needed; until then, regulatory scrutiny of acceptable daily intakes should be revisited.